Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be willing to sign and date a consent form before taking part in the study.
- You must be 18 years old or older at the time of joining the study.
- You must have been diagnosed with relapsing multiple sclerosis (RMS) based on specific medical guidelines from 2017.
- Your level of disability, measured on a standard scale, must fall within a certain range (from no disability up to needing some help walking — confirm with trial site).
- You must have regular check-ups that include MRI brain or spine scans.
- You must be willing to provide blood samples during the study.
- You must be willing to take part in health assessments, including physical examinations and questionnaires.
Who may not be able to join:
- You or your legal guardian have decided you do not wish to continue or participate.
- You are currently pregnant.
- You have been diagnosed with a serious brain infection called Progressive Multifocal Leukoencephalopathy (PML).
- You have had a severe allergic reaction to the medicine being studied.
- There has been a breach of the study rules that puts your safety at risk.
- You have developed certain serious health conditions, such as cancer, severe liver failure, or serious ongoing infections like active hepatitis B or HIV.
- You have abnormal blood or lab test results that the medical team believes make it unsafe for you to continue in the study.
- You have any other health condition that the medical team believes makes it unsafe for you to take part.
- You have not been following the study instructions or taking the study medicine as required.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Ofatumumab treatment reduces sNfL levels in patients with Relapsing Multiple Sclerosis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.